Liquid Biopsy Market Size

  • Report ID: 69
  • Published Date: Oct 03, 2024
  • Report Format: PDF, PPT

Global Liquid Biopsy Market TOC

  1. Market Definition
    1. Market Definition
    2. Market Segmentation
    3. Product Overview
  2. Research Methodology
    1. Research Process
    2. Primary Research
      1. Manufacturers
      2. End-users
    3. Secondary research
    4. Market size estimation
  3. Executive Summary- Global Liquid Biopsy Market
  4. Analysis of Market Dynamics
    1. Drivers
    2. Restraints
    3. Opportunities
    4. Trends
  5. Regulatory & Standards Landscape
  6. Pricing Analysis
  7. Epidemiology Analysis
  8. Impact of COVID-19 on the Liquid Biopsy Market
    1. Pre-COVID-19 Scenario, 2017-19
    2. COVID-19 scenario, 2020
    3. Post-COVID-19 scenario
  9. Comparative Analysis (Liquid biopsy vs Tissue-based biopsy)
  10. End-User Usability Analysis
  11. Competitive Structure
  12. Global Liquid Biopsy Market Outlook
    1. Global Liquid Biopsy Market Segmentation Analysis 2019-2028
      1. By Product, 2019-2028F (in USD Million)
        1.                           Tools, 2019-2028F (USD Million)
          1. Next generation sequencing (NGS), 2019-2028F (USD Million)
          2. Polymerase chain reaction (PCR), 2019-2028F (USD Million)
          3. Microarrays, 2019-2028F (USD Million)
        2. Assay kits & reagents, 2019-2028F (USD Million)
        3. Services, 2019-2028F (USD Million)
      2. By Biomarker Type, 2019-2028F (in USD Million)
        1. Circulating Tumor Cells, 2019-2028F (USD Million)
        2. Circulating Tumor DNA, 2019-2028F (USD Million)
        3. Exosomes, 2019-2028F (USD Million)
        4. Circulating RNA & Proteins, 2019-2028F (USD Million)
        5. Nucleosomes, 2019-2028F (USD Million)
      3. By Sample, 2019-2028F (in USD Million)
        1. Blood, 2019-2028F (USD Million)
        2. Urine, 2019-2028F (USD Million)
        3. Others, 2019-2028F (USD Million)
      4. By Clinical Application, 2019-2028F (in USD Million)
        1. Early Disease Screening, 2019-2028F (USD Million)
        2. Therapy Selection, 2019-2028F (USD Million)
        3. Treatment Response Monitoring, 2019-2028F (USD Million)
        4. Molecular Health Monitoring, 2019-2028F (USD Million)
        5. Others, 2019-2028F (USD Million)
      5. By Disease Indication, 2019-2028F (in USD Million)
        1. Lung Cancer, 2019-2028F (USD Million)
        2. Colorectal Cancer, 2019-2028F (USD Million)
        3. Breast Cancer, 2019-2028F (USD Million)
        4. Prostate Cancer, 2019-2028F (USD Million)
        5. Liver Cancer, 2019-2028F (USD Million)
        6. Head & Neck Cancer, 2019-2028F (USD Million)
        7. Others, 2019-2028F (USD Million)
      6. By End-User, 2019-2028F (in USD Million)
        1. Hospitals, 2019-2028F (USD Million)
        2. Clinics, 2019-2028F (USD Million)
        3. Research Laboratories, 2019-2028F (USD Million)
        4. Academic Institutes, 2019-2028F (USD Million)
        5. Others, 2019-2028F (USD Million)
      7. By Region, 2019-2028F (in USD Million)
        1. North America, 2019-2028F (in USD Million)
        2. Europe, 2019-2028F (in USD Million)
        3. Asia Pacific, 2019-2028F (in USD Million)
        4. Latin America, 2019-2028F (in USD Million)
        5. Middle East & Africa, 2019-2028F (in USD Million)
  13. North America Liquid Biopsy Market Outlook
    1. North America Liquid Biopsy Market Segmentation Analysis 2019-2028
      1. By Product, 2019-2028F (in USD Million)
      2. By Biomarker Type, 2019-2028F (in USD Million)
      3. By Sample, 2019-2028F (in USD Million)
      4. By Clinical Application, 2019-2028F (in USD Million)
      5. By Disease Indication, 2019-2028F (in USD Million)
      6. By End-User, 2019-2028F (in USD Million)
      7. By Country, 2019-2028F (in USD Million)
  14. Latin America Liquid Biopsy Market Outlook
    1. Latin America Liquid Biopsy Market Segmentation Analysis 2019-2028
      1. By Product, 2019-2028F (in USD Million)
      2. By Biomarker Type, 2019-2028F (in USD Million)
      3. By Sample, 2019-2028F (in USD Million)
      4. By Clinical Application, 2019-2028F (in USD Million)
      5. By Disease Indication, 2019-2028F (in USD Million)
      6. By End-User, 2019-2028F (in USD Million)
      7. By Country, 2019-2028F (in USD Million)
  15. Europe Liquid Biopsy Market Outlook
    1. Europe Liquid Biopsy Market Segmentation Analysis 2019-2028
      1. By Product, 2019-2028F (in USD Million)
      2. By Biomarker Type, 2019-2028F (in USD Million)
      3. By Sample, 2019-2028F (in USD Million)
      4. By Clinical Application, 2019-2028F (in USD Million)
      5. By Disease Indication, 2019-2028F (in USD Million)
      6. By End-User, 2019-2028F (in USD Million)
      7. By Country, 2019-2028F (in USD Million)
  16. Asia Pacific Liquid Biopsy Market Outlook
    1. Asia Pacific Liquid Biopsy Market Segmentation Analysis 2019-2028
      1. By Product, 2019-2028F (in USD Million)
      2. By Biomarker Type, 2019-2028F (in USD Million)
      3. By Sample, 2019-2028F (in USD Million)
      4. By Clinical Application, 2019-2028F (in USD Million)
      5. By Disease Indication, 2019-2028F (in USD Million)
      6. By End-User, 2019-2028F (in USD Million)
      7. By Country, 2019-2028F (in USD Million)
  17. Middle East & Africa Liquid Biopsy Market Outlook
    1. Middle East & Africa Liquid Biopsy Market Segmentation Analysis 2019-2028
      1. By Product, 2019-2028F (in USD Million)
      2. By Biomarker Type, 2019-2028F (in USD Million)
      3. By Sample, 2019-2028F (in USD Million)
      4. By Clinical Application, 2019-2028F (in USD Million)
      5. By Disease Indication, 2019-2028F (in USD Million)
      6. By End-User, 2019-2028F (in USD Million)
      7. By Country, 2019-2028F (in USD Million)
  18. Competitive Structure
    1. Qiagen
    2. F. Hoffmann-La Roche Ltd
    3. Bio-Rad Laboratories, Inc.
    4. Illumina, Inc.
    5. Inivata Limited
    6. Agena Bioscience, Inc.
    7. Thermo Fisher Scientific
    8. Guardant Health, Inc.

Liquid Biopsy Market Size

Liquid Biopsy Market size was valued at USD 5.96 billion in 2023 and is expected to reach USD 26.93 billion by 2036, expanding at around 12.3% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of liquid biopsy is evaluated at USD 6.55 billion.

The growth of the liquid biopsy market can be attributed to the increasing advancements in medical research, as well as the rising concern for the increasing prevalence of chronic diseases worldwide. Global cancer incidences are on the rise, with breast cancer being the most prevalent among all cancers. The increase in cancer occurrences drives technological advances for diagnostic and treatment fields to ensure cancer detection and treatment and decrease the mortality rates. All cancers release various cells, genetic material, and other cellular components into the bloodstream that can be used to detect specific markers to diagnose them. Liquid biopsy has seen significant advancements in technology and a rise in its clinical and research application. While tissue biopsy remains the gold standard in cancer diagnosis and treatment, liquid biopsy in conjunction with other diagnostic approaches can be vital in diagnosing cancers as treatment at an early stage has a higher probability of cure. According to the statistical report GLOBOCAN 2020 released by the International Agency for Research on Cancer (IARC), stated that in the year 2020, a total of 19.3 Million cancer cases were registered globally. Moreover, a total of 10 Million deaths caused due to cancer was also registered in the same year.

Furthermore, tremendous progress has been made in all medicine sectors, both diagnostic and curative, in the global healthcare system. The advancement of non-invasive or minimally invasive therapies, more precise diagnostics employing artificial intelligence, and telemedicine breakthroughs are paving the way for better infrastructure with composite solutions for diverse conditions at an accessible price. However, due to a lack of regulatory standards in particular developing countries and other policies that prohibit the use of liquid biopsy in hospitals, liquid biopsy remains minimal. As a result, only a few hospitals and research institutions utilize liquid biopsy, which is expected to hamper the liquid biopsy market growth during the forecast period. 


Liquid Biopsy Market Overview
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 69
  • Published Date: Oct 03, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing incidence of cancer and, rising research and development activities are the major factors responsible for the growth of the market.

The market is anticipated to attain a CAGR of 30.7% over the forecast period i.e., 2020-2028.

High regulatory standards associated with biopsy procedures is estimated to act as barriers to the market growth.

Asia Pacific is estimated to create notable growth opportunities for market growth over the forecast period.

The major players in the market are Qiagen, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Illumina, Inc., Inivata Limited, Agena Bioscience, Inc., Thermo Fisher Scientific, Guardant Health, Inc. and others.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample